NYSE: HQL - Tekla Life Sciences Investors

Yield per half year: +16.72%
Sector: Financials

Share chart Tekla Life Sciences Investors

Extended chart Simple chart
Financial Markets by TradingView

About

Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies.

More details
It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Выручка -0.0693
EBITDA -0.0705
Число акций ао 0.02679 млрд
P/E 3.35
P/S -5.04
P/BV 0.9105
EV/EBITDA -4.95
Цена ао 13.52
Сайт https://www.teklacap.com/hql.html
Див.доход ао 10.45
Дивиденд ао 0.87
Валюта usd
ISIN US87911K1007
IPO date 1992-05-04
Sector Financials
Industry Capital Markets
Валюта отчета usd
Change price per day: 0% (14.94)
Change price per week: +0.2685% (14.9)
Change price per month: -2.23% (15.28)
Change price per 3 month: -0.8626% (15.07)
Change price per half year: +16.72% (12.8)
Change price per year: +24.29% (12.02)
Change price per 3 year: -24.96% (19.91)
Change price per 5 year: -4.35% (15.62)
Change price per year to date: +26.83% (11.78)
All parameters

Underestimation

Title Value Grade
P/S 14.11 1
P/BV 0.8259 9
P/E 14.85 8
EV/EBITDA 14.85 7
Total: 7.63

Efficiency

Title Value Grade
ROA, % 5.55 2
ROE, % 5.56 2
Total: 4.33

Dividends

Title Value Grade
Div yield, % 10.2 10
DSI 0.8571 8.57
Total: 6.4

Debt

Title Value Grade
Debt/EBITDA 0 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % -133.94 0
Yield Ebitda, % -131.71 0
Yield EPS, % -126.15 0
Total: 0
More

Institutions Volume Share, %
Saba Capital Management, L.P. 1421300 5.42
Cornerstone Advisors, LLC 494340 1.89
1607 Capital Partners, LLC 480179 1.83
Allspring Global Investments Holdings, LLC 454154 1.73
Morgan Stanley 430266 1.64
AQR Arbitrage LLC 384231 1.47
Clough Capital Partners, LP 375410 1.43
RPO LLC 338542 1.29
Needham Investment Management, L.L.C. 313792 1.2
Flagship Harbor Advisors, LLC 264003 1.01

ETF Share, % Profitability for 1 year, % Dividends, %
Saba Closed End Funds ETF 2.8917 21.584699453552 2.29022
First Trust Income Opportunities ETF 0.4681 18.299445471349 2.48805
Amplify High Income ETF 2.263 6.9359086918349 2.77149



Head Job title Payment Year of birth
Dr. Daniel R. Omstead M.S, Ph.D. Principal Executive Officer, President and Trustee N/A 1953 (71 year)
Mr. Peter Branner Chief Investment Officer N/A 1964 (60 years)

Address: United States, Boston. MA, 100 Federal Street - open in Google maps, open in Yandex maps
Website: https://www.teklacap.com/hql.html